Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Study:

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Rationale:

n/a

Purpose:

This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).

Study Status: Recruiting

Recruiting:
Elizabeth Gazdick 216-445-8907 gazdice@ccf.org

Condition Intervention Phase
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Drug: brentuximab vedotin
Drug: rituximab
Phase 2

Verified by Seattle Genetics, Inc. December, 2013

Sponsored by: Seattle Genetics, Inc.
Information provided by: Seattle Genetics, Inc.
ClinicalTrials.gov identifier: NCT01421667

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic, The
Cleveland, Ohio 44195
United States

Dana Kennedy, PharmD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site